Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging
The podcast marks a new initiative in the Company's ongoing mission to inform and engage broader global audiences about innovations in breast imaging. Through accessible and engaging conversations, the series will explore the evolving landscape of breast cancer detection, highlighting clinical challenges, market dynamics, and the technologies poised to reshape the industry and patient care.
In the premiere episode, listeners will hear a compelling discussion about the limitations of current imaging tools, including mammography, digital breast tomosynthesis, ultrasound, and MRI, particularly in screening women with dense breast tissue, who represent approximately 50% of the population. With breast cancer projected to affect over 315,000 women in the U.S. in 2025, the episode highlights the urgent need for imaging technologies that offer earlier, more accurate detection and a better patient experience.
The podcast draws on insights from recent industry data, regulatory updates, and the Company's own developments, offering a fresh perspective on Izotropic's mission and its flagship product, IzoView, a first-of-its-kind dedicated Breast CT Imaging System.
This new communications platform repackages publicly disclosed information into a conversational format that's both educational and accessible to patients, healthcare professionals, and stakeholders across the breast health ecosystem. The Company intends to use the podcast to support broader awareness-building efforts as it advances IzoView toward regulatory approval and market launch.
Episode 1 of the podcast is available now on the Company's YouTube channel. Subscribe to stay informed about future episodes covering breast imaging trends, patient advocacy, and medical imaging innovation.
Podcast Sources Cited:
Izotropic Corporation (July 29, 2025) Izotropic's IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies. [Press Release]. https://www.investorwire.com/newsarticle/?qmstory=5535744170701878
Izotropic Corporation (August 5, 2025) Izotropic's IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers [Press Release]. https://www.investorwire.com/newsarticle/?qmstory=8776674626207663
Murphy, H. (2025, July 10). Over 100 AI-enabled radiology algorithms added to FDA's list of approvals. Health Imaging. Retrieved July 14, 2025, from https://healthimaging.com/topics/healthcare-management/healthcare-policy/over-100-ai-enabled-radiology-algorithms-added-fdas-list-approvals?utm_source=newsletter&utm_medium=hi_news_alert
Carey, L. (2025, July 14). Radiology drives July FDA AI-enabled medical device update. Aunitminnie.com. Retrieved July 14, 2025, from https://www.auntminnie.com/imaging-informatics/artificial-intelligence/article/15750598/radiology-drives-july-fda-aienabled-medical-device-update?utm_campaign=2025-07-19&utm_source=AuntMinnie-Letter+From+The+Editor&since=1752987600000&braze_int_id=64e760629860e800019ad93c&braze_ext_id=6430325219ef38833c537806&utm_medium=email
Allegretto, A. (2025, July 14). Rural women more prone to advanced-stage breast cancer. Aunitminnie.com. Retrieved July 14, 2025, from https://www.auntminnie.com/clinical-news/womens-imaging/article/15750577/rural-women-more-prone-to-advancedstage-breast-cancer?utm_campaign=2025-07-15&utm_source=AuntMinnie-Letter+From+The+Editor&since=1752642000000&braze_int_id=64e760629860e800019ad93c&braze_ext_id=6430325219ef38833c537806&utm_medium=email
Murphy, H. (2025, July 16). Reimbursement for contrast-enhanced mammography is on the rise. Health Imaging. Retrieved July 16, 2025, from https://healthimaging.com/topics/medical-imaging/womens-imaging/reimbursement-contrast-enhanced-mammography-rise?utm_source=newsletter&utm_medium=hi_news
Murphy, H. (2025, July 15). GPT-4o's 'all or nothing' accuracy continues to hinder its radiologic capabilities. Health Imaging. Retrieved July 16, 2025, from https://healthimaging.com/topics/artificial-intelligence/gpt-4os-all-or-nothing-accuracy-continues-hinder-its-radiologic-capabilities?utm_source=newsletter&utm_medium=hi_weekly
About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.
Disclaimer & Forward-Looking Statements:This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.Podcast episodes are generated with the assistance of Google AI. Content was produced using generative tools and may contain machine-generated elements. Listeners are encouraged to verify all information through official sources.
Contacts:
Robert Thast, Interim Chief Executive Officer Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1 Email: bthast@izocorp.com
James Gagnon, International Communications Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
General and Corporate Inquiries Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3 Email: info@izocorp.com
Corporate CommunicationsIBNAustin, Texaswww.InvestorBrandNetwork.com512.354.7000 OfficeEditor@InvestorBrandNetwork.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
He felt 'chased' by anxiety and got help online. Now that resource experts trust could be shut down
Joey Laguio remembers waking up every morning in high school with a sense of dread. "It felt like always being chased by something," said Laguio, now 33 and living in Vancouver. After he enrolled in engineering at the University of British Columbia, his first major panic attack hit. Breathing was hard and he trembled, consumed with worries over what others thought of him, he said. From a counsellor in Vancouver, Laguio learned that he had anxiety, and was referred to Anxiety Canada, a registered charity offering resources online for people with anxiety and obsessive compulsive disorder (OCD). "The specific resources were helpful to me because I could access them at any time I wanted to and also because they were a good complement to the therapy I was doing," Laguio said. Now, however, some mental health experts are worried Anxiety Canada's online resources will cease to be available next April if the organization that had funding cut by the B.C. government earlier this year doesn't find a new source of revenue. They say patients, families and mental health professionals will lose a carefully curated and trustworthy source for mental health information, tips and tools just as misinformation proliferates. 'Worried about what's going to happen' Dr. Julie Eichstedt, a child psychologist in London, Ont., said although anxiety disorders are very treatable, access to resources is a concern. "I'm worried about what's going to happen to all those people that have been dependent on these [Anxiety Canada] resources," Eichstedt said. There's "really nothing compatible for me to send families to." Linda Campbell of Nanoose Bay, on Vancouver Island, said she was caught by surprise several years ago when her outwardly happy son told her one day when he was in Grade 3 that it was all too much. Campbell initially equated anxiety with stress and overscheduling her son. Then they found a child psychiatrist who suggested Anxiety Canada. "I knew I could trust it," Campbell said. "Every health-care provider said go here because we know what you're going to get, so we have a framework between us to have conversations. I don't think I even realized the importance of it at the time." About one in four people will deal with levels of debilitating anxiety at some point in their lifetime, leaving them unable to work at their full capacity, said Maureen Whittal, a psychologist who co-founded Anxiety Canada in 1999 and is chair of its volunteer board. Socially, anxiety can interfere with relationships, including marriage and parenting, she said. Increases in generalized anxiety disorder Statistics Canada says generalized anxiety disorder doubled among those aged 15 and older between 2012 and 2022, rising from 2.6 per cent to 5.2 per cent. Young women 24 and under showed the largest increases. Anxiety Canada saw $223,200 in provincial funding removed earlier this year and scaled back its services. It is now a skeleton organization relying on a few volunteers but no paid employees. Its MindShift app, which was shut down when the funding was removed, had more than 1.5 million downloads in 2024, with tens of thousands of monthly users, including teens. A published study showed use of the app reduced anxiety and stigma and Whittal hopes it could resume if further founding is found. Some of Anxiety Canada's online resources continue to be available as it winds down its services. Campbell, who is a member of a support group for parents whose children have anxiety disorders, said people will grasp onto what they think will offer quick and easy solutions. "They're kind of in a desperate moment and they think that this will solve their problem," she said. "I think that's why it's really important to say: 'Here's what we know is proven techniques.'" Earlier this year, Anxiety Canada also wound down its educational podcasts and TikTok videos modelling best practices and cut an online cognitive behaviour treatment program as its funding was reduced. Eichstedt said she recommends Anxiety Canada to parents and teachers because all the evidence-based content and practical examples are in one place, setting it apart from other services. Guide to effective treatments For children, avoidance behaviours are one of the hallmarks of anxiety, Eichstedt said. They may miss school, not participate in class or make friends. Marks can go down because the student is afraid to ask for help or can't complete their homework. "There may be lots of tears, there could be tantrums," Eichstedt said. But left untreated, anxiety tends to persist and can fuel other problems like depression. Treating anxiety is important to make sure kids develop as they're supposed to, she said. WATCH | Overcoming the stigma around mental health struggles: Robert Roopa, a psychologist and psychotherapist in York Region, north of Toronto, said he often refers to Anxiety Canada's articles and videos. "If the site is no longer available, I'm concerned that an increasing number of people who need OCD and anxiety support will not receive the appropriate treatment," Roopa said. Then the patient loses time and money on what doesn't help their specific problems. Filling a 'critical gap' Dr. Peggy Richter, a psychiatrist in Toronto who heads the Frederick W. Thompson Anxiety Disorder Centre at Sunnybrook Health Sciences Centre, says that ideally, people would see a live therapist for help. "But we recognize across Canada with our geography that that [isn't] always feasible and people with expertise in how to treat the anxiety disorder psychologically are very often very hard to find covered by OHIP or provincial health-care systems," said Richter, who also specializes in OCD. "MindShift was filling a really critical gap." The B.C. government's Mental Health and Substance Use Services (BCMHSUS), which provides specialized services in the province, said it issued a contract this year worth about $1 million to BC Partners. Anxiety Canada had been of member of the partners, a group of mental health and substance use organizations, but was no longer included by the government this year. The 2025/26 funding is half of the $2 million given the previous year, BCMHSUS said. "While this is less than last year's contract, it is a substantial contribution to health literacy. The other funds were directed towards critical front-line services supporting the care and recovery of people with mental health disorders." B.C.'s Health Ministry said its relationship with Anxiety Canada through BCMHSUS ended earlier this year. No further provincial funding will be available for Anxiety Canada for the next fiscal year, beginning in April. To revert to full service would take $1 million annually, Whittal said. Eichstedt is organizing a letter-writing campaign to try to save the now volunteer-run group. She'd like to see federal funding for Anxiety Canada as a national resource and program for anxiety and related disorders. Laguio, the Vancouver resident, said Anxiety Canada complemented the cognitive behaviour therapy sessions his parents paid for with a psychologist. As a teen and young adult, Laguio said he dreaded even the thought of driving. "I would have existential crises of like: 'What if I what if I hurt someone or like someone's life ends because of me?'" LISTEN | Trying to get people to talk about OCD: Some days he'd stick with what he called a "two" on a 10-point fear scale of Anxiety Canada's fear ladder exercise, where you list actions you'd typically steer clear of and then slowly work through them. For him, it started with driving around a quiet block at night. Now, Laguio calls the cognitive behaviour therapy received through Anxiety Canada "foundational" to managing his relationships and work. Laguio said as a non-profit, he felt Anxiety Canada had his best interests at heart. "It was free," he said. "As someone who was really struggling with my career and finances, that's kind of what I needed."
Bloomberg
2 hours ago
- Bloomberg
Whoop Refuses to Remove Blood Pressure Tool Despite FDA Warning
Whoop Inc., the maker of screen-less fitness bands, said it will not disable its blood-pressure tracking tool despite a request from the US Food and Drug Administration. The FDA last month sent a warning letter to Whoop stating that the company's Blood Pressure Insights feature, which both measures blood pressure and provides related feedback, means that the Whoop is operating as a medical device.
Yahoo
5 hours ago
- Yahoo
Kuros Biosciences Reports First Half of 2025 Results
Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million) Direct MagnetOs™ sales increased by 77% to USD 62.7 million in H1 2025 (H1 2024: USD 35.4 million) The Group achieved its first-ever operating profit, reaching USD 3.5 million, compared to an operating loss of USD (0.2) million in H1 2024 Total Group EBITDA reached USD 5.1 million in H1 2025 (H1 2024: USD 0.8 million) and total Group adjusted EBITDA* amounted to USD 7.8 million in H1 2025, equaling a margin of 12.3% (H1 2024: USD 4.5 million at 12.6%). After amortization, depreciation, the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million) Cash position remains strong while funding strategic growth initiatives and investing in working capital, with cash and cash equivalents totaling USD 18.4 million as of June 30, 2025 (December 31, 2024: USD 19.8 million) Reporting currency changed from CHF to USD to align with the Group's primary market and operational footprint in the U.S. The Group continues to expect sales growth of at least 60% in 2025 and anticipates sales of between USD 220 million and USD 250 million by 2027 Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences ('Kuros' or the 'Company') a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue reached USD 63.5 million, marking a growth of 78% compared to H1 2024. Revenue from Direct MagnetOs product sales increased 77% year-on-year to USD 62.7 million (H1 2024: USD 35.4 million). The company achieved an operating profit of USD 3.5 million in the first half of 2025, marking its first positive operating result, up from an operating loss of USD (0.2) million in H1 2024. The Group achieved an EBITDA of USD 5.1 million in H1 2025, increasing from USD 0.8 million in H1 2024. Adjusted EBITDA* totaled at USD 7.8 million, up from USD 4.5 million in H1 2024. This represents an adjusted EBITDA* margin of 12.3%. The Group does not expect a material impact from U.S. tariffs in 2025. Finally, the reporting currency was changed from Swiss francs (CHF) to U.S. dollars (USD) to reflect the Group's primary market and business activities. Chris Fair, Chief Executive Officer of Kuros Biosciences, said: 'We recorded exceptional company revenue growth of 78%, marking a pivotal phase of scale and impact for Kuros. An outstanding accomplishment is that the group has for the first time ever recorded an operating profit. With FDA clearance and U.S. launch of MagnetOs MIS, accelerating growth in extremities, and entry into new international markets, we continue to deliver with innovation, precision, and purpose. The strategic alliance with Medtronic is expanding our reach across U.S. spine markets, while our new Atlanta headquarters will enable domestic production and an immersive educational experience for surgeons, partners, and investors. Backed by strong financial performance, an experienced and diverse board, and momentum across all segments, we are well-positioned to sustain growth and create long-term value for patients, providers, and shareholders globally.' Commercial, Operational & Regulatory Highlights Medtronic U.S. Spine Partnership Gains Traction – In January 2025, Kuros finalized a five-year exclusive strategic sales agent agreement with the Medtronic spinal division for MagnetOs in mutually agreed upon U.S. sales territories. The partnership, which evolved from a successful pilot, is accelerating commercial access and hospital entry across key geographies, serving as a major force multiplier for Kuros' U.S. growth. FDA Clearance & First Cases with MagnetOs MIS Delivery System – Kuros has received FDA 510(k) clearance for its MagnetOs MIS Delivery System, a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine procedures. The system enables three times faster graft placement compared to traditional funnel-based methods, combining precise delivery with compelling Level I clinical data.1,2 Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. 'MagnetOs MIS delivered smooth, precise graft placement in a typically challenging MIS TLIF case – no preparation, no thawing, just immediate delivery and efficiency. It pairs streamlined handling with compelling clinical data, making it a meaningful advancement for surgeons who value both efficiency and biologically robust healing,' said Dr. Park. Continued Momentum in Extremities Market – With an established team dedicated to the extremities segment, Kuros is laying the groundwork for long-term success. Early progress has been promising, and the team continues to focus on targeted surgeon and distributor engagement, training, and brand awareness through an omnichannel strategy that includes key scientific meetings and driving social media presence. Global Expansion Accelerates – Following recent approval of MagnetOs Granules, ANVISA has now approved MagnetOs Putty for use in Brazil, further expanding Kuros' commercial presence in the growing South American spine market and building on recent global clearances in Lebanon and beyond. First Capital Markets Day Successfully Completed – In May 2025, Kuros hosted its inaugural Capital Markets Day in Zurich, welcoming over 130 attendees in-person and online. The event showcased the company's scientific leadership, global commercial strategy, and clinically proven differentiated approach to bone healing – featuring insights from a leading U.S. foot and ankle surgeon on how bone graft choice directly impacts patient outcomes and day-to-day quality of life. In addition, the Group presented the progress made in transforming its business from a functional, structural and digital perspective. New U.S. Headquarters and Production Facility Construction Underway – As part of its U.S. operational expansion strategy, Kuros has secured a location in Atlanta for a new office and manufacturing facility. The site is expected to support diversified manufacturing and enable Kuros to scale operations and engagement in line with accelerating demand for MagnetOs, with an immersive experience for surgeons, partners, and investors—highlighting the science, innovation, and clinical impact of MagnetOs in an engaging environment. Net operating costs Cost of goods sold amounted to USD 7.1 million in H1 2025 (H1 2024: USD 3.9 million) of which USD 0.9 million (H1 2024: USD 0.9 million) relate to the amortization of capitalized R&D. Net operating costs from continuing operations amounted to USD 52.8 million in H1 2025, compared to USD 32.0 million in the prior year period. Sales and marketing costs increased from USD 20.7 million in H1 2024 to USD 37.4 million in H1 2025, primarily driven by an expanded sales force and higher sales and distribution expenses, in line with the Group's continued commercial expansion. The increase also reflects the initial investments to penetrate the extremities and international markets, supporting future revenue growth and a broader market reach. Research and development costs of continuing operations increased from USD 3.6 million in H1 2024 to USD 4.3 million in H1 2025. This is primarily driven by increased R&D activities, clinical trial expenditures, and higher personnel expenses due to an increase in headcount, reflecting the Group's ongoing commitment to innovation to support long-term growth. General and administrative costs increased from USD 7.8 million in H1 2024 to USD 11.1 million in H1 2025. The increase was mainly driven by the scaling up of back-office functions and building the digital infrastructure to support business growth. Operating profit/ (loss) and group net result The operating profit from continuing operations amounted to USD 3.5 million (H1 2024: operating loss from continuing operations of USD (0.2) million). After accounting for the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million). Financial position and other assets Cash and cash equivalents amounted to USD 18.4 million as of H1 2025 (December 31, 2024: USD 19.8 million). The decrease in cash balance compared to year-end 2024 is mainly attributable to ongoing investments in growth initiatives and working capital to support rising demand. Funds available (including trade and other receivables) for financing the operations of Kuros amounted to USD 45.3 million as of H1 2025. This is an increase of USD 7.8 million from USD 37.5 million as of December 31, 2024. As of H1 2025, total intangible assets amounted to USD 17.6 million (2024: USD 16.4 million) and goodwill amounted to USD 24.2 million (2024: USD 21.3 million). Outlook Kuros expects MagnetOs to continue its strong growth trajectory in the spine and extremity segments, gaining further market share in the U.S., Europe and the rest of the world, and launching in additional countries. The company remains sufficiently financed to support its planned organic growth path and continues to expect robust sales growth of at least 60% in 2025. Based on the solid performance in the first half of the year, Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction. Key figures H1 2025 H1 2024Restated In TUSD, IFRS Revenue from product sales 63,480 35,684 Cost of goods sold (7,148) (3,896) Gross profit 56,332 31,788 Sales and marketing costs (37,394) (20,723) Research and development costs (4,305) (3,610) General and administrative costs (11,136) (7,826) Other income 6 126 Net operating costs (52,829) (32,033) Operating profit/ (loss) 3,503 (245) Net finance result (3,366) 1,857 Profit before tax 137 1,612 Income taxes (2,173) (1,466) Net (loss)/ profit from continuing operations (2,036) 146 Profit/ (loss) from discontinued operation, net of tax 23 (382) Net loss (2,013) (236) Net loss per share from continuing operations (in USD) (0.05) 0.00 Net loss per share (in USD) (0.05) (0.01) June 30, 2025 Dec 31, 2024Restated Cash and cash equivalents 18,442 19,762 Trade and other receivables 26,886 17,698 Half Year Report 2025The Kuros Biosciences Half Year Report 2025 can be downloaded via the following link on our website: Kuros Biosciences Interim Report 2025 Half Year Results 2025 – WebcastKuros will host a virtual webcast to discuss H1 2025 financial results on August 14, 2025, at 3:00pm CET. Investors can join the webcast via the following link: Investor Webcast RegistrationThe respective presentation can be downloaded via the following link:Kuros Biosciences WebCast H1 2025 Upcoming EventsOctober 16, 2025 – Trading Update Q3 2025 For further information, please contact:Kuros Biosciences AG Alexandre Müller Daniel Geiger Investor Relations Chief Financial Officer Tel +41 43 268 32 31 Tel +41 44 733 47 41 IR@ Growing bone with MagnetOsTM gives surgeons confidence where it matters most – delivering predictable fusion outcomes.2 In a Level I human clinical study published in Spine, MagnetOs achieved nearly twice the fusion rate (79% vs. 47%) of autograft in posterolateral fusions (PLFs).2 Among active smokers – who made up 1 in 5 patients – the fusion difference between MagnetOs and autograft was even more dramatic.**†2,3 MagnetOs grows bone on its own thanks to NeedleGripTM – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth, without added cells or growth factors.‡§4-9 Ready-to-use, easy to mold, and reliably staying put10, MagnetOs carries no intrinsic risk of human tissue-related disease transmission and is FDA cleared for use throughout the spine, including interbody procedures. ¶6-9 Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions. Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. * Adjusted EBITDA excludes recurring and one-time share-based compensation and the relevant social security charges** 19 of initial 100 patients were active smokers.† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.2‡ Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit § MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft. ¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA & mixed with autograft in posterolateral spine & intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space. Data on file. MagnetOs MIS. Stempels, et al. Spine. 2024;49(19):1323-1331. van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024. van Dijk, et al. eCM. 2021;41:756-73. van Dijk, et al. J Immunol Regen Med. 2023;19:100070. Instructions for Use (IFU) MagnetOs Granules. Instructions for Use (IFU) MagnetOs Putty. Instructions for Use (IFU) MagnetOs Easypack Putty. Instructions for Use (IFU) MagnetOs Flex Matrix. Data on file. MagnetOs Putty and MagnetOs Easypack Putty. Attachment Kuros Biosciences Press Release H1 2025 Results
